Middle East & Africa Checkpoint Inhibitors Market Research Report – Segmented By Type, Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis ( 2025 to 2033 )
The checkpoint inhibitors market size in the Middle East & Africa was valued at USD 1.63 billion in 2025. The regional market is expected to reach USD 14.20 billion by 2033 from USD 2.07 billion in 2025, growing at a CAGR of 27.19 % during the forecast period.
Checkpoint inhibitors are a class of immunotherapy drugs that work by blocking certain proteins on immune cells, allowing the body’s immune system to recognize and attack cancer cells more effectively. These therapies have transformed the treatment paradigm for several cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. According to the World Cancer Research Fund, approximately 400,000 new cancer cases were reported in the African continent in 2020, with projections indicating a sharp increase in the coming decades. Additionally, the International Agency for Research on Cancer (IARC) estimates that cancer mortality in the MEA region will rise by over 50% by 2030 if current trends persist.
One of the primary drivers of the MEA checkpoint inhibitors market is the increasing prevalence of various types of cancer across the region. According to the International Agency for Research on Cancer (IARC), there were over 600,000 new cancer cases recorded in the Middle East and Africa in 2020 alone. This figure is expected to surge significantly, with projections suggesting an increase of nearly 70% by 2030 due to aging populations, lifestyle changes, and environmental factors. The growing burden of these diseases has led to increased demand for advanced treatment modalities beyond traditional chemotherapy and radiation. Checkpoint inhibitors offer a promising alternative by leveraging the body's own immune system to target and destroy cancer cells. Moreover, rising awareness among medical professionals and patients regarding the benefits of immunotherapy has further accelerated the uptake of checkpoint inhibitors. Clinical trials conducted by major pharmaceutical companies in collaboration with regional hospitals have demonstrated significant response rates in treating advanced-stage cancers, reinforcing confidence in these therapies.
Another significant driver fueling the growth of the MEA checkpoint inhibitors market is the surge in government and private sector investments aimed at strengthening oncology infrastructure and expanding access to advanced cancer therapies. Countries across the Gulf Cooperation Council (GCC), particularly Saudi Arabia and the United Arab Emirates, have launched ambitious healthcare modernization programs under their broader Vision 2030 and Centennial 70 strategic plans, respectively. In parallel, private healthcare providers are also stepping up their efforts. These facilities are increasingly adopting immunotherapy-based treatment protocols, including checkpoint inhibitors, for managing various forms of cancer. Furthermore, public-private partnerships are playing a pivotal role in accelerating drug approvals and reducing time-to-market for novel oncology products. Regulatory bodies such as the Saudi Food and Drug Authority (SFDA) and the Dubai Healthcare City (DHCC) have streamlined approval processes for life-saving medications, which is aligning them more closely with international standards.
The high cost associated with these therapies is ascribed to limit the growth of the MEA checkpoint inhibitors market. Checkpoint inhibitors, such as pembrolizumab, nivolumab, and ipilimumab, are among the most expensive cancer treatments available globally. In countries like Egypt, Nigeria, and Yemen, where per capita healthcare expenditure remains low, the affordability of these therapies poses a major challenge. Even in wealthier Gulf states such as Saudi Arabia and the UAE, where healthcare budgets are more substantial, the economic burden of providing checkpoint inhibitors to a growing number of cancer patients presents a sustainability challenge. Additionally, the lack of comprehensive insurance coverage or reimbursement policies for immunotherapies in much of the MEA region exacerbates the financial barrier.
Another critical restraint affecting the MEA checkpoint inhibitors market is the limited awareness and expertise regarding immunotherapy administration among healthcare professionals and the general population. This lack of trained personnel directly impacts the ability of hospitals and clinics to administer checkpoint inhibitors safely and effectively. Moreover, the absence of standardized guidelines for immunotherapy use in many MEA countries contributes to inconsistent treatment approaches and underutilization of these drugs. Furthermore, logistical challenges such as cold chain storage requirements and the need for infusion centers capable of handling intravenous immunotherapies add another layer of complexity.
One of the most promising opportunities driving the MEA checkpoint inhibitors market is the increasing number of clinical trials and research collaborations being conducted in the region. Over the past few years, pharmaceutical companies and academic institutions have recognized the untapped potential of the MEA region for conducting oncology-related clinical studies. Notably, countries such as Saudi Arabia, the United Arab Emirates, and South Africa have emerged as key hubs for clinical research due to their relatively well-developed healthcare infrastructures and growing pool of oncology specialists. Moreover, multinational biopharmaceutical firms such as Merck & Co., Bristol-Myers Squibb, and Roche have initiated collaborative agreements with local healthcare providers to conduct phase III and IV trials for immunotherapeutic agents. These partnerships not only accelerate drug approvals but also enhance local expertise and improve patient access to novel therapies.
An emerging opportunity shaping the MEA checkpoint inhibitors market is the increasing adoption of precision medicine and biomarker testing in oncology care. Precision medicine involves tailoring cancer treatments based on individual genetic profiles and tumor characteristics, enabling more effective and personalized therapeutic interventions. Biomarker testing, particularly for PD-L1 expression levels and tumor mutational burden (TMB), plays a crucial role in identifying patients who are most likely to benefit from checkpoint inhibitors. In the MEA region, several leading cancer centers are now incorporating molecular profiling into routine clinical practice. Additionally, governments in the Gulf Cooperation Council (GCC) countries are investing heavily in genomics research and digital health infrastructure to support precision oncology.
A major challenge facing the MEA checkpoint inhibitors market is the lack of harmonized regulatory frameworks across the region. Unlike mature markets such as the United States and Europe, where centralized regulatory authorities streamline drug approvals, the MEA region comprises multiple jurisdictions with varying registration processes, clinical trial requirements, and reimbursement policies. This fragmentation significantly delays the availability of checkpoint inhibitors in many countries. In North Africa and Sub-Saharan Africa, regulatory agencies often lack sufficient resources and technical expertise to evaluate complex biologics such as checkpoint inhibitors efficiently. According to the Access to Medicines Coalition, the average time for a novel oncology drug to reach the market in countries like Egypt and Kenya exceeds 24 months, compared to just 6–8 months in Western Europe.
Another pressing challenge confronting the MEA checkpoint inhibitors market is the limited patient access caused by underdeveloped distribution networks and supply chain inefficiencies. Checkpoint inhibitors are typically high-value, temperature-sensitive biologic drugs that require stringent storage conditions and specialized logistics for transportation. According to the World Bank, only about 40% of healthcare facilities in Sub-Saharan Africa have reliable electricity, which is essential for maintaining the cold storage required for biologics. Even in more developed economies within the region, such as the UAE and Qatar, checkpoint inhibitors are predominantly available through a handful of tertiary care hospitals and specialty pharmacies, limiting access for patients residing outside major urban centers. Furthermore, the lack of trained pharmacists and supply chain professionals proficient in handling biologic drugs adds another layer of complexity. These systemic challenges restrict the equitable distribution of checkpoint inhibitors, preventing many cancer patients from receiving potentially life-extending treatments.
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| CAGR | 27.19 % |
| Segments Covered | By Type, Application and Country. |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Country Covered | KSA, UAE ,Israel, rest of GCC countries South Africa ,Ethiopia, Kenya, Egypt, Sudan ,Rest of MEA |
| Market Leader Profiled | Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd. |
The PD-1 inhibitors held 40.2% of the MEA checkpoint inhibitors market share in 2024 owing to the widespread adoption of PD-1-targeted therapies such as pembrolizumab and nivolumab across a broad spectrum of cancers, including non-small cell lung cancer (NSCLC), melanoma, and Hodgkin lymphoma. As per Global Oncology Trends 2023 published by the American Society of Clinical Oncology (ASCO), PD-1 inhibitors have demonstrated superior efficacy and broader applicability compared to other immunotherapeutic agents, contributing to their high prescription rates.
The increasing number of regulatory approvals and label expansions granted to PD-1 inhibitors is propelling the growth of the segment. Additionally, clinical evidence supporting improved survival outcomes with PD-1 inhibitors has reinforced physician confidence.
The Chimeric Antigen Receptor T-cell (CAR-T) therapy segment is likely to gain huge traction with a CAGR of 28.3% in the next coming years. One major driver behind this rapid growth is the rising incidence of blood cancers in the region. As reported by the World Cancer Research Fund, approximately 75,000 new cases of leukemia and lymphoma were diagnosed in the MEA region in 2022. The limited availability of curative treatment options beyond chemotherapy and stem cell transplants has created a compelling need for novel cellular therapies like CAR-T. Moreover, leading academic medical centers in countries such as Israel, UAE, and South Africa are actively participating in global trials and establishing specialized treatment centers for adoptive cell therapy.
The lung cancer treatment segment was accounted in holding 35.3% of MEA checkpoint inhibitors market share in 2024. Also, the integration of checkpoint inhibitors into national treatment guidelines is prompting the growth of the market. For instance, the Saudi Ministry of Health updated its oncology protocols in 2022 to include pembrolizumab-based regimens as standard-of-care for advanced NSCLC patients with high PD-L1 expression. This shift has significantly increased prescription rates across public and private hospitals in the country. Another contributing factor is the rising smoking prevalence in parts of the MEA region. As per the World Health Organization (WHO), tobacco use affects over 25% of adults in Gulf Cooperation Council (GCC) countries, directly contributing to higher lung cancer incidence.
The melanoma treatment segment is emerging quickly with an anticipated CAGR of 22.3% in the next coming years. According to the World Cancer Research Fund, the incidence of melanoma in Egypt, Morocco, and the United Arab Emirates has increased by approximately 12% over the past five years , partly due to prolonged sun exposure and changing lifestyle patterns. A key driver of this segment’s rapid expansion is the growing availability of targeted treatment options. Additionally, regional healthcare providers, including institutions in Israel and South Africa, are increasingly adopting immune checkpoint inhibitors as part of combination regimens, improving overall survival rates. Moreover, public health campaigns promoting early detection and skin cancer screening are gradually gaining momentum.
Saudi Arabia was the largest contributor with 28.3% of the MEA checkpoint inhibitors market share in 2024. A key driver of market growth is the increasing burden of cancer, particularly lung and breast cancer. According to the Saudi Health Council, cancer incidence in the country has risen by more than 40% since 2015, which is prompting greater adoption of advanced therapies. Additionally, the Saudi Food and Drug Authority (SFDA) has expedited drug approvals, bringing checkpoint inhibitors such as pembrolizumab and nivolumab to market faster than in many neighboring countries. Collaborations between international pharmaceutical firms and local institutions, such as King Faisal Specialist Hospital & Research Centre, are also enhancing clinical research capabilities and patient access.
The United Arab Emirates was positioned second by holding 19.2% of the MEA checkpoint inhibitors market share in 2024. One of the key growth drivers is the presence of world-class cancer treatment centers, including Sheikh Khalifa Medical City and Cleveland Clinic Abu Dhabi, which offer immunotherapy services backed by trained oncologists and advanced diagnostics. According to the Dubai Health Authority (DHA), the number of immunotherapy prescriptions in the UAE rose by 30% between 2021 and 2023. Additionally, the country’s proactive regulatory environment, including fast-track approvals for oncology drugs, enhances market accessibility.
Israel is likely to gain huge traction with significant CAGR in the next coming years. A key driver of Israel’s strong market position is its robust clinical research ecosystem. Institutions such as Sheba Medical Center and Tel Aviv University are actively involved in global immunotherapy trials, contributing to faster drug approvals and broader treatment adoption. Additionally, the country’s universal healthcare coverage ensures that a large portion of the population can access checkpoint inhibitors with minimal financial barriers.
South Africa is projected to have steady growth opportunities with the rising cancer burden in urban centers. According to the National Cancer Registry of South Africa, over 120,000 new cancer cases were diagnosed in 2022, with melanoma, breast, and cervical cancers being the most prevalent. Private health insurers, including Discovery Health and Momentum Health, have started covering certain immunotherapy regimens, increasing patient access. Additionally, leading academic hospitals such as Chris Hani Baragwanath Academic Hospital and Tygerberg Hospital are conducting clinical trials in collaboration with global pharmaceutical companies, which is enhancing treatment availability and expertise.
Egypt checkpoint inhibitors market growth is fuelled by the government’s efforts to improve cancer care through initiatives such as the “100 Million Healthy Lives” campaign, which includes early cancer screening programs. Additionally, partnerships between multinational pharmaceutical companies and local distributors have facilitated the availability of checkpoint inhibitors in private hospitals and select public institutions.
Some of the key companies leading the Middle East & Africa Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.
The competition in the MEA checkpoint inhibitors market is intensifying as global pharmaceutical giants expand their presence in the region to capitalize on rising cancer incidence and improving healthcare infrastructure. While multinational biopharmaceutical companies dominate due to their established product portfolios and robust R&D pipelines, local and regional players are gradually gaining traction by offering cost-effective alternatives and leveraging government support. The market remains highly consolidated, with a few key players controlling the majority of the therapeutic landscape, particularly in wealthier Gulf states where regulatory frameworks are more developed and healthcare spending is higher.
However, in lower-income countries, affordability and limited awareness continue to restrict market penetration, allowing generic manufacturers and non-profit initiatives to play a supplementary role. Strategic collaborations between international firms and domestic entities are becoming increasingly common to navigate regulatory complexities and build localized distribution networks. Additionally, competitive pressures are mounting as companies seek to differentiate themselves through innovative pricing models, patient support programs, and digital health integrations.
Merck & Co. plays a dominant role in the MEA checkpoint inhibitors market through its flagship drug, pembrolizumab, a PD-1 inhibitor that has become a cornerstone in cancer immunotherapy globally. The company’s extensive R&D capabilities and strategic partnerships with regional healthcare providers have enabled it to establish a strong presence across key MEA markets. Merck actively engages in clinical trial collaborations and patient access programs aimed at expanding immunotherapy adoption in emerging economies.
Bristol-Myers Squibb is another leading player, known for its pioneering work in immune checkpoint therapy with drugs like nivolumab and ipilimumab. The company has been instrumental in introducing combination immunotherapy regimens that are now widely used in treating melanoma, lung cancer, and other malignancies. In the MEA region, Bristol-Myers Squibb focuses on regulatory engagement and capacity-building initiatives to enhance physician training and improve treatment accessibility.
Roche contributes significantly to the MEA checkpoint inhibitors market with its PD-L1 inhibitor, atezolizumab. Roche's commitment to personalized medicine and biomarker-driven therapies aligns well with the growing emphasis on precision oncology in the region.
One of the primary strategies employed by key players in the MEA checkpoint inhibitors market is expanding regional partnerships and collaborations with academic institutions, government bodies, and private hospitals to facilitate clinical trials and accelerate drug approvals. These alliances help companies navigate complex regulatory landscapes while increasing their visibility among local medical professionals.
Another major strategy involves enhancing market access through pricing and reimbursement models, which is including patient assistance programs and risk-sharing agreements. By tailoring financial solutions to the economic conditions of different countries, pharmaceutical firms aim to make checkpoint inhibitors more affordable and accessible to broader patient populations.
Companies are increasingly focusing on capacity building and education initiatives, such as training oncologists, pharmacists, and nurses on immunotherapy protocols. This not only improves treatment outcomes but also fosters long-term trust and dependency on specific brands within the healthcare ecosystem of the MEA region.
In January 2023, Merck & Co. expanded its collaboration with the King Hussein Cancer Center in Jordan to conduct joint clinical trials on pembrolizumab, which is aiming to evaluate its efficacy in diverse patient populations across the Middle East.
In August 2023, Bristol-Myers Squibb partnered with the Dubai Health Authority to launch an oncology training program focused on equipping healthcare professionals with the knowledge and skills required for administering checkpoint inhibitors.
In March 2024, Roche signed a memorandum of understanding with South Africa’s National Cancer Registry to support data collection and real-world evidence generation for immunotherapy treatments in sub-Saharan Africa.
In November 2024, AstraZeneca initiated a patient access initiative in Egypt in collaboration with local distributors to provide subsidized atezolizumab treatment for low-income patients diagnosed with advanced-stage cancers.
In June 2025, Novartis launched a digital health platform in Saudi Arabia to streamline immunotherapy prescription management and enhance patient monitoring through AI-powered analytics and telemedicine integration.
This research report on the Middle East and Africa checkpoint inhibitors market has been segmented and sub-segmented into the following categories.
By Drug
By Application
By Country
Frequently Asked Questions
Checkpoint inhibitors are a type of immunotherapy that help the immune system recognize and attack cancer cells by blocking proteins (like PD-1, PD-L1, and CTLA-4) that suppress immune responses.
Countries such as Saudi Arabia, the UAE, South Africa, and Egypt are leading in adoption due to advanced healthcare systems, investment in oncology, and access to innovative therapies.
Coverage varies by country. In wealthier nations like the UAE and Saudi Arabia, many checkpoint inhibitors are covered. In other regions, out-of-pocket expenses remain a barrier.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region